Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 10:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 287 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hypotrichosis Clear all
Completed Phase 2 Interventional Results available

A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing

NCT02503137
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
Topical SM04554 solution, Topical vehicle solution
Drug
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Clinton Township, Michigan • Cleveland, Ohio • College Station, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 9, 2026, 10:43 PM EDT
Completed Phase 1 Interventional Results available

Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for the Treatment of Chemotherapy-Induced Alopecia

NCT01588522
View directory record Official record
Conditions
Chemotherapy-Induced Alopecia
Interventions
Compound 31543 Calcitriol 5 μg/mL, Compound 31543 Calcitriol 10 μg/mL, Compound 31543 Calcitriol 20 μg/mL, Compound 31543 Calcitriol 40 μg/mL, Compound 31543 Calcitriol 60 ug/mL, Compound 31543 Calcitriol 80 μg/mL
Drug
Lead sponsor
BPGbio
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 9, 2026, 10:43 PM EDT
Withdrawn Phase 4 Interventional

Hydraderm for Androgenic Alopecia

NCT05426629
View directory record Official record
Conditions
Androgenic Alopecia
Interventions
Venus Glow
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Oct 9, 2026, 10:43 PM EDT
Completed Phase 2Phase 3 Interventional Results available

PF-06651600 for the Treatment of Alopecia Areata

NCT03732807
View directory record Official record
Conditions
Alopecia Areata
Interventions
PF-06651600 Induction Dose, PF-06651600 Maintenance Dose #1, PF-06651600 Maintenance Dose #2, PF-06651600 Maintenance Dose #3, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
46
States / cities
Birmingham, Alabama • Beverly Hills, California • Irvine, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 9, 2026, 10:43 PM EDT
Recruiting Phase 2 Interventional

Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata

NCT06747611
View directory record Official record
Conditions
Alopecia Areata, Alopecia Totalis, Alopecia Universalis
Interventions
Vancomycin, Neomycin and MTT capsules, Placebo capsules
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 9, 2026, 10:43 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004541)

NCT01451138
View directory record Official record
Conditions
Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions
Autologous cultured dermal and epidermal cells
Biological
Lead sponsor
Aderans Research Institute
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
4
States / cities
Birmingham, Alabama • Tucson, Arizona • Pinellas Park, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2013 · Synced Oct 9, 2026, 10:43 PM EDT
Recruiting Phase 3 Interventional

A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

NCT05723198
View directory record Official record
Conditions
Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical
Interventions
Baricitinib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 17 Years
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
44
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Encinitas, California + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 9, 2026, 10:43 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata

NCT06826196
View directory record Official record
Conditions
Alopecia Areata (AA)
Interventions
ALD-102 Solution, Placebo or Control
Drug · Other
Lead sponsor
Aldena Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Thousand Oaks, California • West Lafayette, Indiana • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 9, 2026, 10:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

LLLT for Alopecia of the Eyebrow in Women

NCT04897555
View directory record Official record
Conditions
Alopecia
Interventions
LLLT
Device
Lead sponsor
Freedom Laser Therapy, Inc.
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
2
States / cities
Mendham, New Jersey • Great Neck, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2021 · Synced Oct 9, 2026, 10:43 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Fraxel Laser for Alopecia

NCT03284021
View directory record Official record
Conditions
Alopecia
Interventions
Fractional erbium-glass 1550 nm laser
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Oct 9, 2026, 10:43 PM EDT
Active, not recruiting No phase listed Observational

Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib

NCT06531109
View directory record Official record
Conditions
Alopecia Areata
Interventions
Ritlecitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
28
States / cities
Birmingham, Alabama • Montgomery, Alabama • Fremont, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 9, 2026, 10:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Follicular Revival in Androgenic Alopecia: Evaluating Use of Micro-needling

NCT04341363
View directory record Official record
Conditions
Androgenic Alopecia
Interventions
Tattoo machine
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 9, 2026, 10:43 PM EDT
Not listed Phase 2 Interventional

Investigate the Efficacy and Safety of Farudodstat Compared With Its Placebo in Adult Alopecia Areata Participants

NCT05865041
View directory record Official record
Conditions
Alopecia Areata
Interventions
Farudodstat, Placebo
Drug
Lead sponsor
ASLAN Pharmaceuticals
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
19
States / cities
Birmingham, Alabama • Fountain Valley, California • Santa Ana, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Oct 9, 2026, 10:43 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of Hair Stimulating Complex (HSC) in Female Pattern Hair Loss

NCT03662854
View directory record Official record
Conditions
Alopecia
Interventions
Hair Stimulating Complex (HSC), Phosphate Buffered Saline
Biological · Other
Lead sponsor
Histogen
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Oct 9, 2026, 10:43 PM EDT
Completed No phase listed Observational

Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the US

NCT07226531
View directory record Official record
Conditions
Alopecia Areata
Interventions
Ritlecitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 9, 2026, 10:43 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

To Evaluate Efficacy, Safety, and Tolerability of KX-826 in Male Subjects With Androgenetic Alopecia

NCT05218642
View directory record Official record
Conditions
Alopecia, Male Pattern Hair Loss
Interventions
KX- 826 dosed at 2.5mg, KX-826 dosed at 5mg, Matching placebo to KX-826
Drug
Lead sponsor
Suzhou Kintor Pharmaceutical Inc,
Industry
Eligibility
18 Years to 70 Years · Male only
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
10
States / cities
Fountain Valley, California • Hialeah, Florida • Hialeah Gardens, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 9, 2026, 10:43 PM EDT
Completed Phase 3 Interventional Results available

A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata

NCT03899259
View directory record Official record
Conditions
Alopecia Areata
Interventions
Baricitinib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
33
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fremont, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 9, 2026, 10:43 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

A Study of PRP Treatment for Hair Loss After Cancer Therapy in Women With Breast Cancer

NCT04459650
View directory record Official record
Conditions
Alopecia
Interventions
Platelet Rich Plasma system
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 9, 2026, 10:43 PM EDT
Terminated Phase 1 Interventional

A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer

NCT05622058
View directory record Official record
Conditions
Prevention of Chemotherapy-induced Myelosuppression
Interventions
ALRN-6924, TAC (doxorubicin 50 mg/m2; cyclophosphamide 500 mg/m2; docetaxel 75 mg/m2)
Drug
Lead sponsor
Aileron Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
5
States / cities
Tamarac, Florida • Huntersville, North Carolina • Wilson, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Oct 9, 2026, 10:43 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

PAI-1 Expression in Non-scarring Hair Loss

NCT02548689
View directory record Official record
Conditions
Androgenetic Alopecia, Telogen Effluvium, Alopecia Areata
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Oct 9, 2026, 10:43 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Characteristics of T Cells From Alopecia Areata Scalp Skin Before and After Treatment With Aldara 5%

NCT00176943
View directory record Official record
Conditions
Alopecia Areata
Interventions
Aldara Cream 5%
Drug
Lead sponsor
Hordinsky, Maria K., MD
Individual
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2002
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 9, 2026, 10:43 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

NCT04784533
View directory record Official record
Conditions
Alopecia Areata
Interventions
CTP-543, Placebo
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
39
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 9, 2026, 10:43 PM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males

NCT02781311
View directory record Official record
Conditions
Alopecia
Interventions
Setipiprant, Placebo, Finasteride
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 49 Years · Male only
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
18
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2019 · Synced Oct 9, 2026, 10:43 PM EDT
Completed Phase 3 Interventional Results available

Clinical Trial in Females for Female Pattern Hair Loss

NCT01226459
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
5% Minoxidil Topical Foam, Vehicle Topical Foam
Drug
Lead sponsor
Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • Wichita, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2014 · Synced Oct 9, 2026, 10:43 PM EDT